New combination chemotherapy of cisplatin with an electron-donating compound for treatment of multiple cancers

Zhang, Qinrong; Lu, Qing‐Bin

doi:10.1038/s41598-020-80876-z

Cited by 30 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin mouse models have been used to investigate pharmacokinetics and tissue distribution of cisplatin [15][16][17], the repair capacity of cisplatin-DNA adducts [18], the molecular mechanisms of cisplatin toxicity [19][20][21][22][23] and to test a new generation of platinumbased chemotherapy drugs or adjunctive therapies [24][25][26][27][28][29][30][31][32][33][34][35], or other potential agents or strategies to prevent or treat cisplatin toxicities [36][37][38][39][40][41].…”

Section: Cisplatin Mouse Modelsmentioning

confidence: 99%

Cisplatin Mouse Models: Treatment, Toxicity and Translatability

Perše

2021

Biomedicines

View full text Add to dashboard Cite

Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of pediatric and adult malignances. However, it has various side effects which limit its use. Cisplatin mouse models are widely used in studies investigating cisplatin therapeutic and toxic effects. However, despite numerous promising results, no significant improvement in treatment outcome has been achieved in humans. There are many drawbacks in the currently used cisplatin protocols in mice. In the paper, the most characterized cisplatin protocols are summarized together with weaknesses that need to be improved in future studies, including hydration and supportive care. As demonstrated, mice respond to cisplatin treatment in similar ways to humans. The paper thus aims to illustrate the complexity of cisplatin side effects (nephrotoxicity, gastrointestinal toxicity, neurotoxicity, ototoxicity and myelotoxicity) and the interconnectedness and interdependence of pathomechanisms among tissues and organs in a dose- and time-dependent manner. The paper offers knowledge that can help design future studies more efficiently and interpret study outcomes more critically. If we want to understand molecular mechanisms and find therapeutic agents that would have a potential benefit in clinics, we need to change our approach and start to treat animals as patients and not as tools.

show abstract

Section: Cisplatin Mouse Modelsmentioning

confidence: 99%

Cisplatin Mouse Models: Treatment, Toxicity and Translatability

Perše

2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Cisplatin is the cornerstone agent for ovarian cancer; however, its use is often restricted because of its toxic side effects [37]. Thus, we combined cisplatin with an effective and safe agent for the treatment approach.…”

Section: Discussionmentioning

confidence: 99%

Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer

Park

Suh

Kim

et al. 2021

IJMS

View full text Add to dashboard Cite

Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent. However, the anti-tumor effects of DFMO in ovarian cancer cells have not been entirely understood. Our study aimed to identify the effects and mechanism of DFMO in epithelial ovarian cancer cells using SKOV-3 cells. Treatment with DFMO resulted in a significantly reduced cell viability in a time- and dose-dependent manner. DFMO treatment inhibited the activity and downregulated the expression of ODC in ovarian cancer cells. The reduction in cell viability was reversed using polyamines, suggesting that polyamine depletion plays an important role in the anti-tumor activity of DFMO. Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO. We also found that the effect of DFMO was mediated by AP-1 through the activation of upstream JNK via phosphorylation. Moreover, DFMO enhanced the effect of cisplatin, thus showing a possibility of a synergistic effect in treatment. In conclusion, treatment with DFMO alone, or in combination with cisplatin, could be a promising treatment for ovarian cancer.

show abstract

“…The use of traditional drugs in chemotherapy is associated with many problems such as low water solubility, cytotoxicity, side effects and drug resistance [86][87][88]. A number of potential new drug delivery systems is based on combination therapy that can solve these problems [89,90]. This therapy involves co-administration of drugs that work by different mechanisms against cancer cells.…”

Section: Combination Therapy Involving Cisplatin and Other Drugsmentioning

confidence: 99%

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview

Piorecka

Kurjata

Stańczyk

2021

IJMS

View full text Add to dashboard Cite

The development in the area of novel anticancer prodrugs (conjugates and complexes) has attracted growing attention from many research groups. The dangerous side effects of currently used anticancer drugs, including cisplatin and other platinum based drugs, as well their systemic toxicity is a driving force for intensive search and presents a safer way in delivery platform of active molecules. Silicon based nanocarriers play an important role in achieving the goal of synthesis of the more effective prodrugs. It is worth to underline that silicon based platform including silica and silsesquioxane nanocarriers offers higher stability, biocompatibility of such the materials and pro-longed release of active platinum drugs. Silicon nanomaterials themselves are well-known for improving drug delivery, being themselves non-toxic, and versatile, and tailored surface chemistry. This review summarizes the current state-of-the-art within constructs of silicon-containing nano-carriers conjugated and complexed with platinum based drugs. Contrary to a number of other reviews, it stresses the role of nano-chemistry as a primary tool in the development of novel prodrugs.

show abstract

New combination chemotherapy of cisplatin with an electron-donating compound for treatment of multiple cancers

Cited by 30 publications

References 39 publications

Cisplatin Mouse Models: Treatment, Toxicity and Translatability

Cisplatin Mouse Models: Treatment, Toxicity and Translatability

Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview

Contact Info

Product

Resources

About